Bristol-Myers misses main goal of late-stage skin cancer trial

Bristol-Myers Squibb Co said on Wednesday a late-stage trial testing a combination of its cancer drugs missed a main goal of preventing skin cancer from recurring in a certain group of patients, sending its shares down nearly 1%.